Long-term microbiome and clinical effects of a microbiome-guided personalized diet versus low-FODMAP diet in irritable bowel syndrome: A 12-month follow-up randomized controlled trial.
Gut MicrobesAug 20, 2026 (epub)
Varol Tunali, Naciye Çiğdem Arslan, Gözde Derviş Haki̇m et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicenter randomized controlled trial evaluated the long-term effects of a microbiome-guided personalized diet (PD) versus a low-FODMAP diet (LFD) in adults with irritable bowel syndrome (IBS). At 12 months, PD maintained significant symptom improvement (IBS-SSS reduction of -78.3 points) compared to LFD, which regressed (+29.3 points; p = 0.001).
Key findings
- PD maintained symptom improvement at 12 months with an IBS-SSS reduction of -78.3 points.
- Responder rates for IBS-SSS were higher with PD (62.5%) compared to LFD (34.5%; p = 0.029).
- PD was associated with sustained increases in Shannon alpha-diversity at 12 months (+0.205; p < 0.01).
Why it matters
Understanding the long-term effects of dietary interventions in IBS can guide clinicians in recommending effective management strategies. The sustained benefits of a microbiome-guided diet may enhance patient outcomes and quality of life.